医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BeiGene Announces Addition of Dr. Ronald Levy to Scientific Advisory Board

2014年03月03日 PM10:25
このエントリーをはてなブックマークに追加


 

BEIJING

BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the addition of Dr. Ronald Levy, M.D., to its Scientific Advisory Board. Dr. Levy is Professor of Medicine, Director of the Lymphoma Program and Former Chief of the Division of Oncology at Stanford University.

“We are delighted to welcome Ron to our SAB, with his in-depth expertise in lymphoma and immune-oncology and his extensive experience in the drug discovery process,” said John V. Oyler, Chief Executive Officer of BeiGene. “Ron has been a pioneer in the field of immunotherapy for lymphoma indications, including research that has helped elucidate the molecular underpinnings of the disease, and his subsequent work on specific drug development makes him a valuable addition to our team of advisors as we work to develop novel therapeutics that can address these areas of high unmet need for patients.”

“BeiGene is a leader in the oncology space with a novel translational research platform and unique patient access that has already produced several exciting targeted and immune-oncology drug candidates,” said Dr. Levy. “I look forward to working with their noteworthy team of scientists and advisors to bring these therapeutics through clinical development and to patients in need of additional treatment options.”

Dr. Levy is a member of the National Academy of Sciences and the Institute of Medicine. He was the first clinician to successfully treat human lymphoma with a monoclonal antibody, and also made important contributions to the development of rituximab (Rituxan®) for the treatment of lymphoma. Dr. Levy has received international acclaim for his work in the field, including the Karnofsky Award from the American Society of Clinical Oncology, the Medal of Honor by the American Cancer Society, the Armand Hammer Award for Cancer Research, the General Motors Charles Kettering Prize, the Damashek Prize from the American Society of Hematology, and the King Faisal International Prize in Medicine.

Dr. Levy joins Drs. Neal Rosen, Charles Sawyers, David Schenkein, Xiaodong Wang and Steve Young on BeiGene’s Scientific Advisory Board.

About BeiGene (Beijing), Co., Ltd.

BeiGene is an innovative Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics through a novel translational research platform that combines unique access to internal patient-derived biopsies with strong oncology biology. With a team of 150 scientists and staff, its pipeline is comprised of novel oral small molecules and monoclonal antibodies for cancer. BeiGene Ltd. is a Cayman Islands exempted company that is an investor in and collaborator with BeiGene (Beijing), Co. Ltd. For more information, please visit our website at www.beigene.com.

CONTACT

Media/Investors:
BeiGene (Beijing), Co., Ltd.
Jesse
Baumgartner, 212-362-1200
pr@beigene.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • レスメド後援の研究で在宅酸素療法と在宅非侵襲的換気療法の併用が費用対効果の高いCOPD治療法であると判明
  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結